{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:29:21Z","timestamp":1794022161572,"version":"4.8.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s10067-021-05794-5","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T15:42:33Z","timestamp":1622648553000},"page":"3185-3193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"40","author":[{"given":"Xinyu","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuotong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingsi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,2]]},"reference":[{"issue":"3","key":"5794_CR1","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/cei.13238","volume":"195","author":"M Brown","year":"2019","unstructured":"Brown M, O\u2019Reilly S (2019) The immunopathogenesis of fibrosis in systemic sclerosis. Clin Exp Immunol 195(3):310\u2013321. https:\/\/doi.org\/10.1111\/cei.13238","journal-title":"Clin Exp Immunol"},{"issue":"10103","key":"5794_CR2","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D (2017) Systemic sclerosis. Lancet 390(10103):1685\u20131699. https:\/\/doi.org\/10.1016\/S0140-6736(17)30933-9","journal-title":"Lancet"},{"key":"5794_CR3","doi-asserted-by":"publisher","unstructured":"Allanore Y, Simms R, Distler O et al (2015) Systemic sclerosis. Nat Rev Dis Prim 1(April 2015). https:\/\/doi.org\/10.1038\/nrdp.2015.2","DOI":"10.1038\/nrdp.2015.2"},{"issue":"6","key":"5794_CR4","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/BOR.0000000000000551","volume":"30","author":"DR Poudel","year":"2018","unstructured":"Poudel DR, Derk CT (2018) Mortality and survival in systemic sclerosis: a review of recent literature. Curr Opin Rheumatol 30(6):588\u2013593. https:\/\/doi.org\/10.1097\/BOR.0000000000000551","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"5794_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12931-019-0980-7","volume":"20","author":"V Cottin","year":"2019","unstructured":"Cottin V, Brown KK (2019) Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res 20(1):1\u201310. https:\/\/doi.org\/10.1186\/s12931-019-0980-7","journal-title":"Respir Res"},{"issue":"3","key":"5794_CR6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S2213-2600(19)30480-1","volume":"8","author":"A Perelas","year":"2020","unstructured":"Perelas A, Silver RM, Arrossi AV, Highland KB (2020) Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med 8(3):304\u2013320. https:\/\/doi.org\/10.1016\/S2213-2600(19)30480-1","journal-title":"Lancet Respir Med"},{"issue":"10","key":"5794_CR7","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","volume":"69","author":"AJ Tyndall","year":"2010","unstructured":"Tyndall AJ, Bannert B, Vonk M et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69(10):1809\u20131815. https:\/\/doi.org\/10.1136\/ard.2009.114264","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"5794_CR8","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/S2665-9913(19)30144-4","volume":"2","author":"AM Hoffmann-Vold","year":"2020","unstructured":"Hoffmann-Vold AM, Maher TM, Philpot EE et al (2020) The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol 2(2):e71\u2013e83. https:\/\/doi.org\/10.1016\/S2665-9913(19)30144-4","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"5794_CR9","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1002\/art.40130","volume":"69","author":"NS Goh","year":"2017","unstructured":"Goh NS, Hoyles RK, Denton CP et al (2017) Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol 69(8):1670\u20131678. https:\/\/doi.org\/10.1002\/art.40130","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"5794_CR10","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1080\/1744666X.2020.1668269","volume":"15","author":"O Distler","year":"2019","unstructured":"Distler O, Volkmann ER, Hoffmann-Vold AM, Maher TM (2019) Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease. Expert Rev Clin Immunol 15(10):1009\u20131017. https:\/\/doi.org\/10.1080\/1744666X.2020.1668269","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"5794_CR11","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76(8):1327\u20131339. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209909","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"5794_CR12","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708\u2013719. https:\/\/doi.org\/10.1016\/S2213-2600(16)30152-7","journal-title":"Lancet Respir Med"},{"issue":"5","key":"5794_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar2534","volume":"10","author":"C Nannini","year":"2008","unstructured":"Nannini C, West CP, Erwin PJ, Matteson EL (2008) Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 10(5):1\u20139. https:\/\/doi.org\/10.1186\/ar2534","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"5794_CR14","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1007\/s00296-011-1967-y","volume":"32","author":"H Poormoghim","year":"2012","unstructured":"Poormoghim H, Lakeh MM, Mohammadipour M, Sodagari F, Toofaninjed N (2012) Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis. Rheumatol Int 32(8):2431\u20132444. https:\/\/doi.org\/10.1007\/s00296-011-1967-y","journal-title":"Rheumatol Int"},{"key":"5794_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/143637","volume":"2012","author":"A Tzouvelekis","year":"2012","unstructured":"Tzouvelekis A, Galanopoulos N, Bouros E, Kolios G, Zacharis G, Ntolios P, Koulelidis A, Oikonomou A, Bouros D (2012) Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. Pulm Med 2012:1\u20137. https:\/\/doi.org\/10.1155\/2012\/143637","journal-title":"Pulm Med"},{"issue":"5","key":"5794_CR16","doi-asserted-by":"publisher","first-page":"e0124205","DOI":"10.1371\/journal.pone.0124205","volume":"10","author":"MA Omair","year":"2015","unstructured":"Omair MA, Alahmadi A, Johnson SR (2015) Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review. Kuwana M, ed. PLoS One 10(5):e0124205. https:\/\/doi.org\/10.1371\/journal.pone.0124205","journal-title":"PLoS One"},{"issue":"7","key":"5794_CR17","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1136\/annrheumdis-2016-210503","volume":"76","author":"AL Herrick","year":"2017","unstructured":"Herrick AL, Pan X, Peytrignet S et al (2017) Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis 76(7):1207\u20131218. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210503","journal-title":"Ann Rheum Dis"},{"key":"5794_CR18","doi-asserted-by":"publisher","unstructured":"Fretheim (2017) Mycophenolate mofetil versus cyclophosphamide in scleroderma-related interstitial lung disease in a real life scenario. (June):4819. https:\/\/doi.org\/10.1136\/annrheumdis-2017-eular.4955","DOI":"10.1136\/annrheumdis-2017-eular.4955"},{"key":"5794_CR19","doi-asserted-by":"publisher","unstructured":"Koneva (2018) Comparison of long-term cyclophosphamide (CY) and mycophenolate mofetil (MMF) efficacy and safety in patients with systemic sclerosis (SSC) and interstitial lung disease (ILD). 16(June):1108.1\u20131108. https:\/\/doi.org\/10.1136\/annrheumdis-2018-eular.1867","DOI":"10.1136\/annrheumdis-2018-eular.1867"},{"issue":"1","key":"5794_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13075-016-1015-0","volume":"18","author":"PD Shenoy","year":"2016","unstructured":"Shenoy PD, Bavaliya M, Sashidharan S, Nalianda K, Sreenath S (2016) Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis. Arthritis Res Ther 18(1):123. https:\/\/doi.org\/10.1186\/s13075-016-1015-0","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"5794_CR21","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00408-013-9499-8","volume":"191","author":"ST Panopoulos","year":"2013","unstructured":"Panopoulos ST, Bournia VK, Trakada G, Giavri I, Kostopoulos C, Sfikakis PP (2013) Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study. Lung 191(5):483\u2013489. https:\/\/doi.org\/10.1007\/s00408-013-9499-8","journal-title":"Lung"},{"issue":"11","key":"5794_CR22","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/art.40560","volume":"70","author":"A Fern\u00e1ndez-Codina","year":"2018","unstructured":"Fern\u00e1ndez-Codina A, Walker KM, Pope JE (2018) Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol 70(11):1820\u20131828. https:\/\/doi.org\/10.1002\/art.40560","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"5794_CR23","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/rheumatology\/key151","volume":"58","author":"D Khanna","year":"2019","unstructured":"Khanna D, Tashkin DP, Denton CP, Lubell MW, Vazquez-Mateo C, Wax S (2019) Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. Rheumatol (United Kingdom) 58(4):567\u2013579. https:\/\/doi.org\/10.1093\/rheumatology\/key151","journal-title":"Rheumatol (United Kingdom)"},{"key":"5794_CR24","doi-asserted-by":"publisher","unstructured":"Rahaghi FF, Strek ME, Southern BD et al (2019) Expert consensus on the screening, treatment, and management of patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), and the potential future role of anti-fibrotics[asterisk] in a treatment paradigm for SSc-ILD: a Delphi consensus study. A7445\u2013A7445. https:\/\/doi.org\/10.1164\/ajrccm-conference.2019.199.1_meetingabstracts.a7445","DOI":"10.1164\/ajrccm-conference.2019.199.1_meetingabstracts.a7445"},{"issue":"9","key":"5794_CR25","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1002\/art.30438","volume":"63","author":"MD Roth","year":"2011","unstructured":"Roth MD, Tseng CH, Clements PJ et al (2011) Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum 63(9):2797\u20132808. https:\/\/doi.org\/10.1002\/art.30438","journal-title":"Arthritis Rheum"},{"issue":"2","key":"5794_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5301\/jsrd.5000237","volume":"2","author":"ER Volkmann","year":"2017","unstructured":"Volkmann ER, Chung A, Tashkin DP (2017) Managing systemic sclerosis-related interstitial lung disease in the modern treatment era. J Scleroderma Relat Disord 2(2):72\u201383. https:\/\/doi.org\/10.5301\/jsrd.5000237","journal-title":"J Scleroderma Relat Disord"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05794-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05794-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05794-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T16:08:42Z","timestamp":1626710922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05794-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,2]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["5794"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05794-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,2]]},"assertion":[{"value":"6 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}